Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Malignant Melanoma

  Free Subscription

Articles published in J Clin Invest

Retrieve available abstracts of 25 articles:
HTML format

Single Articles

    April 2024
  1. ZHAN Y, Guo J, Yang W, Goncalves C, et al
    MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
    J Clin Invest. 2024;134:e181338.

    February 2024
  2. WU M, Hanly A, Gibson F, Fisher R, et al
    The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
    J Clin Invest. 2024 Feb 1:e171063. doi: 10.1172/JCI171063.
    PubMed     Abstract available

    December 2023
  3. KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al
    Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    J Clin Invest. 2023;133:e177489.

    November 2023
  4. AJITH A, Mamouni K, Horuzsko DD, Musa A, et al
    Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
    J Clin Invest. 2023;133:e167951.
    PubMed     Abstract available

    August 2023
  5. HUANG F, Cai F, Dahabieh MS, Gunawardena K, et al
    Peroxisome disruption alters lipid metabolism and potentiates anti-tumor response with MAPK-targeted therapy in melanoma.
    J Clin Invest. 2023 Aug 24:e166644. doi: 10.1172/JCI166644.
    PubMed     Abstract available

    July 2023
  6. OZBAY KURT FG, Lasser S, Arkhypov I, Utikal J, et al
    Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
    J Clin Invest. 2023;133:e170762.
    PubMed     Abstract available

    January 2023
  7. HUUHTANEN J, Kasanen HH, Peltola K, Lonnberg T, et al
    Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients.
    J Clin Invest. 2023 Jan 31:e164809. doi: 10.1172/JCI164809.
    PubMed     Abstract available

    July 2022
  8. HICKMAN A, Koetsier J, Kurtanich T, Nielsen MC, et al
    LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

    June 2022
  9. HUANG H, Nie C, Liu XF, Song B, et al
    Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
    J Clin Invest. 2022 Jun 21. pii: 157726. doi: 10.1172/JCI157726.
    PubMed     Abstract available

    May 2022
  10. PAL S, Perrien DS, Yumoto T, Faccio R, et al
    The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cells homing to bone.
    J Clin Invest. 2022 May 3. pii: 157340. doi: 10.1172/JCI157340.
    PubMed     Abstract available

  11. PAGLIANO O, Morrison RM, Chauvin JM, Banerjee H, et al
    Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

    April 2022
  12. CHEN D, Le SB, Hutchinson TE, Calinescu AA, et al
    Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.
    J Clin Invest. 2022;132.
    PubMed     Abstract available

    January 2022
  13. XU J, Su SM, Zhang X, Chan UI, et al
    ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of non-apoptotic phosphatidylserine.
    J Clin Invest. 2022 Jan 13. pii: 149473. doi: 10.1172/JCI149473.
    PubMed     Abstract available

    November 2021
  14. KRISTENSEN NP, Heeke C, Tvingsholm SA, Borch A, et al
    Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive transfer with tumor-infiltrating lymphocytes in melanoma.
    J Clin Invest. 2021 Nov 23. pii: 150535. doi: 10.1172/JCI150535.
    PubMed     Abstract available

  15. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

    October 2021
  16. PERI A, Greenstein E, Alon M, Pai JA, et al
    Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

  17. CHAKRABORTY B, Byemerwa J, Shepherd JH, Haines CN, et al
    Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
    J Clin Invest. 2021 Oct 12. pii: 151347. doi: 10.1172/JCI151347.
    PubMed     Abstract available

    August 2021
  18. VEATCH JR, Singhi N, Srivastava S, Szeto JL, et al
    A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

    May 2021
  19. GIBLIN W, Bringman-Rodenbarger L, Guo AH, Kumar S, et al
    The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.
    J Clin Invest. 2021 May 4. pii: 138926. doi: 10.1172/JCI138926.
    PubMed     Abstract available

    April 2021
  20. KIM YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, et al
    Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy.
    J Clin Invest. 2021 Apr 29. pii: 145859. doi: 10.1172/JCI145859.
    PubMed     Abstract available

    March 2021
  21. WORREDE A, Douglass SM, Weeraratna AT
    The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

  22. HEEMSKERK N, Gruijs M, Temming AR, Heineke MH, et al
    Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
    J Clin Invest. 2021;131.
    PubMed     Abstract available

  23. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.
    J Clin Invest. 2021 Mar 9. pii: 140752. doi: 10.1172/JCI140752.
    PubMed     Abstract available

    May 2020
  24. LI J, Wang W, Zhang Y, Cieslik M, et al
    Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
    J Clin Invest. 2020;130:2712-2726.
    PubMed     Abstract available

  25. THEIVANTHIRAN B, Evans KS, DeVito NC, Plebanek M, et al
    A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
    J Clin Invest. 2020;130:2570-2586.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.